{"id":4031,"date":"2021-09-27T03:04:15","date_gmt":"2021-09-27T08:04:15","guid":{"rendered":"https:\/\/www.recruit.ie\/?p=4031"},"modified":"2021-09-27T03:05:01","modified_gmt":"2021-09-27T08:05:01","slug":"wuxi-biologics-a-world-leader-in-biologics-manufacturing","status":"publish","type":"post","link":"https:\/\/www.recruit.ie\/careers\/wuxi-biologics-a-world-leader-in-biologics-manufacturing\/","title":{"rendered":"WuXi Biologics, a world leader in biologics manufacturing"},"content":{"rendered":"

We are proud to announce that WuXi Biologics & WuXi Vaccines are sponsors of our next Virtual Recruitment Expo on 30th September. This online jobs fair will be dedicated to the engineering and construction sectors. You can register today for free access here<\/a><\/strong>.<\/p>\n

WuXi Biologics (“WuXi Bio”) (2269.HK), is a global company with leading open-access biologics technology platforms. With operations in Ireland, China, Germany and the U.S., our technology platforms and services are designed to help our global clients shorten the discovery and development time and lower the cost of biologics and vaccines using either microbial fermentation or mammalian cell culture production systems. \u00a0Our global clients include over 450 global partners and 18 of the 20 largest pharmaceutical companies worldwide.\u00a0 Our vision:<\/p>\n

 <\/p>\n

\u201cEvery drug can be made and every disease can be treated\u201d by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry<\/em><\/p>\n

 <\/p>\n

Supported by our strong technical capabilities, extensive experience and state-of-the-art, open-access technology platforms WuXi Biologics allow its customers to initiate a project at any stage in the discovery and development process. We provide 6 biologics discovery platforms for lead identification and characterization, novel bispecific antibody and antibody drug conjugate engineering platforms, robust and novel cell line development technologies and advanced continuous bioprocessing\/biomanufacturing platforms.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Our leadership team consists of one of the largest biologics R&D teams in the world including over 550 Ph.D. scientists with 15-20 years of experience working at the forefront of the biologics industry. While at WuXi Biologics, this team has enabled 8 BLA\/MAA and over 172 worldwide IND submissions in just 6 years, including GMP manufacture of 4 commercial products. Our expertise covers all facets of drug development from early-stage discovery activities to GMP manufacture and release of final drug product. We enable our clients to develop a wide variety of biologics including monoclonal and bispecific antibodies, antibody drug conjugates, Fc-fusion proteins, enzymes, and other recombinant proteins. We also provide development and manufacturing platforms for virus and nucleic acid-based (e.g., plasmid and mRNA) therapeutics and vaccines. We offer comprehensive, integrated and highly customizable end-to-end services and solutions to empower organizations to discover, develop, and manufacture biotherapeutics and vaccines from concept to commercial manufacturing.<\/p>\n

 <\/p>\n

WuXi Biologics provides a quality system and operations that meet worldwide regulatory guidance. Our audit track record demonstrates our commitment to meeting worldwide regulatory standards as validated by GMP manufacturing accreditations from the U.S. FDA, EMA, NMPA, ANVISA and HSA.<\/p>\n

 <\/p>\n

Environmental protection, social responsibility and governance policies are priorities to WuXi Biologics.\u00a0 Our ESG committee is led by the CEO with a focus on pioneering and promoting green practices, giving back to local communities, and continuous improvement in corporate governance.WuXi Biologics has been well recognized for its good ESG performance by: MSCI, DJSI,FTSE Russel.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Our ESG programs include the following essential components:<\/p>\n